---
layout: post
title: New Drug Approvals 2012 - Pt. XXXI - Lomitapide (JuxtapidTM)
date: '2013-01-11T13:33:00.000Z'
author: Rita
tags:
- Small Molecule Drugs
- Black Box Warning Drugs
- 2012 New Drugs
modified_time: '2013-01-11T13:33:02.074Z'
thumbnail: http://3.bp.blogspot.com/-ZFzHEFHPnbw/UOvyk6MKgLI/AAAAAAAAA1k/2bF2N6AMG_Y/s72-c/limotapide.tif
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-7369862814063049794
blogger_orig_url: http://chembl.blogspot.com/2013/01/new-drug-approvals-2012-pt-xxxi.html
---

<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.aegerion.com/Collateral/Images/English-US/Products/Juxtapid_tm_US_rgb_small.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="130" src="http://www.aegerion.com/Collateral/Images/English-US/Products/Juxtapid_tm_US_rgb_small.png" width="200" /></a></div>
<br />
<center face="arial">
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,0,0,1,0,0,0,0,1" width="400" /></center>
<br />
<div style="text-align: center;">
<b>ATC Code:</b> <a href="http://www.whocc.no/atc_ddd_index/?code=C10AX12">C10AX12</a><br />
<b>Wikipedia:</b> <a href="http://en.wikipedia.org/wiki/Lomitapide">Lomitapide</a><br />
<br /></div>
<div style="text-align: justify;">
On December 21<sup>st</sup>, the FDA approved Lomitapide (Tradename: <a href="http://www.trademarkia.com/juxtapid-85802929.html">Juxtapid</a>; Research Codes: BMS-201038-04, BMS-201038, AEGR-733), a <a href="http://en.wikipedia.org/wiki/Microsomal_triglyceride_transfer_protein">Microsomal triglyceride transfer protein (MTP)</a> inhibitor, as a complement to a low-fat diet and other lipid-lowering treatments, in patients with <a href="http://en.wikipedia.org/wiki/Familial_hypercholesterolemia">homozygous familial hypercholesterolemia</a> (HoFH). </div>
<br />
<div style="text-align: justify;">
Familial hypercholesterolemia is a genetic disorder, characterised by high levels of cholesterol rich <a href="http://en.wikipedia.org/wiki/Low-density_lipoprotein">low-density lipoproteins</a> (LDL-C) in the blood. This genetic condition is generally attributed to a faulty mutation in the <a href="http://en.wikipedia.org/wiki/LDL_receptor">LDL receptor (LDLR)</a> gene, which mediates the <a href="http://en.wikipedia.org/wiki/Endocytosis">endocytosis</a> of LDL-C.</div>
<br />
<div style="text-align: justify;">
Lomitapide, trough the inhibition of the microsomal triglyceride transfer protein in the liver, prevents the assembly of <a href="http://en.wikipedia.org/wiki/Apolipoprotein_B">Apoliprotein B-containing lipoproteins</a>, which is required for the formation of LDLs, thus contributing to lower the circulating LDL-C levels.</div>
<br />
<div style="text-align: justify;">
The Microsomal triglyceride transfer protein, which resides in the lumen of the endoplasmic reticulum, is a heterodimer composed of the microsomal triglyceride transfer protein large subunit (Uniprot: <a href="http://www.uniprot.org/uniprot/P55157">P55157</a>; ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL2569">CHEMBL2569</a>), and the <a href="http://en.wikipedia.org/wiki/Protein_disulfide_isomerase">protein disulfide isomerase</a>. Lomitapide binds to the large subunit.<br />
<br />
<pre>&gt;MTP_HUMAN Microsomal triglyceride transfer protein large subunit
MILLAVLFLCFISSYSASVKGHTTGLSLNNDRLYKLTYSTEVLLDRGKGKLQDSVGYRIS
SNVDVALLWRNPDGDDDQLIQITMKDVNVENVNQQRGEKSIFKGKSPSKIMGKENLEALQ
RPTLLHLIHGKVKEFYSYQNEAVAIENIKRGLASLFQTQLSSGTTNEVDISGNCKVTYQA
HQDKVIKIKALDSCKIARSGFTTPNQVLGVSSKATSVTTYKIEDSFVIAVLAEETHNFGL
NFLQTIKGKIVSKQKLELKTTEAGPRLMSGKQAAAIIKAVDSKYTAIPIVGQVFQSHCKG
CPSLSELWRSTRKYLQPDNLSKAEAVRNFLAFIQHLRTAKKEEILQILKMENKEVLPQLV
DAVTSAQTSDSLEAILDFLDFKSDSSIILQERFLYACGFASHPNEELLRALISKFKGSIG
SSDIRETVMIITGTLVRKLCQNEGCKLKAVVEAKKLILGGLEKAEKKEDTRMYLLALKNA
LLPEGIPSLLKYAEAGEGPISHLATTALQRYDLPFITDEVKKTLNRIYHQNRKVHEKTVR
TAAAAIILNNNPSYMDVKNILLSIGELPQEMNKYMLAIVQDILRFEMPASKIVRRVLKEM
VAHNYDRFSRSGSSSAYTGYIERSPRSASTYSLDILYSGSGILRRSNLNIFQYIGKAGLH
GSQVVIEAQGLEALIAATPDEGEENLDSYAGMSAILFDVQLRPVTFFNGYSDLMSKMLSA
SGDPISVVKGLILLIDHSQELQLQSGLKANIEVQGGLAIDISGAMEFSLWYRESKTRVKN
RVTVVITTDITVDSSFVKAGLETSTETEAGLEFISTVQFSQYPFLVCMQMDKDEAPFRQF
EKKYERLSTGRGYVSQKRKESVLAGCEFPLHQENSEMCKVVFAPQPDSTSSGWF
</pre>
</div>
<br />
<div style="text-align: justify;">
There are no known 3D structures for this protein.</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-ZFzHEFHPnbw/UOvyk6MKgLI/AAAAAAAAA1k/2bF2N6AMG_Y/s1600/limotapide.tif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="273" src="http://3.bp.blogspot.com/-ZFzHEFHPnbw/UOvyk6MKgLI/AAAAAAAAA1k/2bF2N6AMG_Y/s320/limotapide.tif" width="320" /></a></div>
<br />
<div style="text-align: justify;">
Lomitapide (IUPAC: N-(2,2,2-trifluoroethyl)-9-{4-[4-({[4'-(trifluoromethyl)biphenyl-2- yl]carbonyl}amino)piperidin-1-yl]butyl}-9H-fluorene-9-carboxamide; Canonical smiles: FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c3ccccc3c4ccc(cc4)C(F)(F)F)c5ccccc5c6ccccc16; PubChem: <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9853053&amp;loc=ec_rcs">9853053</a>; Chemspider: <a href="https://www.chemspider.com/Chemical-Structure.8028764.html?rid=d48cd0ba-f9f9-48b5-b9bb-769a5c1d94be"> 8028764 </a>; ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL354541">CHEMBL354541</a>; Standard InChI Key: MBBCVAKAJPKAKM-UHFFFAOYSA-N) is a synthetic compound with a molecular weight of 693.7 Da, nine hydrogen bond acceptors, two hydrogen bond donors, and has an ALogP of 7.79. The compound is therefore not compliant with the rule of five.</div>
<br />
<div style="text-align: justify;">
Lomitapide is available in the capsular form and the recommended starting daily dose is 5mg, ﻿﻿with the possibility to gradually increase it, based on acceptable safety and tolerability, up to a maximum of 60mg. It has an apparent volume of distribution of 985-1292 L, upon oral administration of a single 60-mg dose, and its absolute bioavailability is 7%. Lomitapide binds extensively to plasma proteins (99.8%). The mean terminal half-life (t<sub>1/2</sub>) of lomitapide is 39.7 hours, being mainly metabolised by CYP3A4. This reliance on CYP3A4 for metabolism leads to multiple opportunities for drug-drug interactions with both CYP3A4 inhibitors and inducers, therefore when combining lomitapide with other lipid-lowering therapies, i.e. statins, a dose adjustment is required.</div>
<br />
<div style="text-align: justify;">
Lomitapide has been given a black box warning due to an increase in transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]) levels after exposure to the drug. </div>
<br />
<div style="text-align: justify;">
The license holder for Juxtapid<sup>TM</sup> is <a href="http://www.aegerion.com/">Aegerion Pharmaceuticals</a>, and the full prescribing information can be found <a href="http://www.blogger.com/www.accessdata.fda.gov/drugsatfda_docs/label/2012/203858s000lbl.pdf">here</a>.</div>
